Vitamin D and pancreatic cancer-an update

Cancers

Volumn 3, Issue 1, 2011, Pages 213-226

  Chiang, Kun Chun ^a   Yeh, Chun Nan ^a   Chen, Tai C ^b  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adenocarcinoma; Chemoprevention; Pancreatic cancer; Prevention; Treatment; Vitamin D; Vitamin D receptor

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; 1ALPHA,25 DIHYDROXYVITAMIN D3 3 BROMOACETATE; CALCITRIOL; COLECALCIFEROL; DOCETAXEL; ERGOCALCIFEROL; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; MART 10; SEOCALCITOL; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DRUG EFFICACY; GENE EXPRESSION; GENOTYPE; HUMAN; LIGHT EXPOSURE; NONHUMAN; OVERALL SURVIVAL; PANCREAS CANCER; REVIEW; TREATMENT RESPONSE; ULTRAVIOLET RADIATION; VITAMIN INTAKE; VITAMIN METABOLISM;

EID: 79953688739     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers3010213     Document Type: Review

References (98)

1. Jemal, A.; Siege, R.; Ward E, Murray T.; Xu, J.; Thun, M.J. Cancer statistics, 2007. CA Cancer J. Clin. 2007, 57, 43-66.
2. American Cancer Society. Cancer Facts and Figures 2008; American Cancer Society: Atlanta, GA, USA, 2008.
3. Trede, M.; Schwall, G.; Saeger, H.D. Survival after pancreatoduodenectmy. 118 Consecutive resections without an operative mortality. Ann. Surg. 1990, 211, 447-458.
4. Yeo, C.J.; Cameron, J.L.; Sohn, T.A.; Lillemoe, K.D.; Pitt, H.A.; Talamini, M.A. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s; pathology, complications, and outcomes. Ann. Surg. 1997, 226, 248-257, discussion 257-260.
5. Nitecki, S.S.; Sarr, M.G.; Colby, T.V.; Heerden, J.A. Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann. Surg. 1995, 221, 59-66.
6. Haller, D.G. New perspectives in the management of pancreas cancer. Semin. Oncol. 2003, 30, 3-10.
7. Raimondi, S.; Maisonneuve, P.; Lowenfels, A.B. Epidemiology of pancreatic cancer: An overview. Nat. Rev. Gastroenterol. Hepatol. 2009, 6, 699-708.
8. Hassan, M.M.; Bondy, M.L.; Wolff, R.A.; Abbruzzese, J.L.; Vauthey, J.N.; Pisters, P.W.; Evans, D.B.; Khan, R.; Chou, T.H.; Lenzi, R.; Jiao, L.; Li, D. Risk factors for pancreatic cancer: Case-control study. Am. J. Gastroenterol. 2007, 102, 2696-2707.
9. Iodice, S.; Gandini, S.; Maisonneuve, P.; Lowenfels, A.B. Tobacco and the risk of pancreatic cancer: A review and meta-analysis. Langenbecks Arch. Surg. 2008, 393, 535-545.
10. Rohrmann, S.; Linseisen, J.; Vrieling, A.; Boffetta, P.; Stolzenberg-Solomon, R.Z.; Lowenfels, A.B.; Jensen, M.K.; Overvad, K.; Olsen, A.; Tjonneland, A.; et al. Ethanol intake and the risk of pancreatic cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Causes Contr. 2009, 20, 785-794.
11. Jiao, L.; Silverman, D.T.; Schairer, C.; Thiébaut, A.C.; Hollenbeck, A.R.; Leitzmann, M.F.; Schatzkin, A.; Stolzenberg-Solomon, R.Z. Alcohol use and risk of pancreatic cancer: The NIH-AARP Diet and Health Study. Am. J. Epidemiol. 2009, 169, 1043-1051.
12. Genkinger, J.M.; Spiegelman, D.; Anderson, K.E.; Bergkvist, L.; Bernstein, L.; van den Brandt, P.A.; English, D.R.; Freudenheim, J.L.; Fuchs, C.S.; Giles, G.G.; et al. Alcohol intake and pancreatic cancer risk: A pooled analysis of fourteen cohort studies. Cancer Epid. Biomark. Prev. 2009, 18, 765-776.
13. Reeves, G.K.; Pirie, K.; Beral, V.; Green, J.; Spencer, E.; Bull, D.; Million Women Study Collaboration. Cancer incidence and mortality in relation to body mass index in the Million Women Study: Cohort study. BMJ 2007, 335, 134.
14. Fryzek, J.P.; Schenk, M.; Kinnard, M.; Greenson, J.K.; Garabrant, D.H. The association of body mass index and pancreatic cancer in residents of southeastern Michigan, 1996-1999. Am. J. Epidemiol. 2005, 162, 222-228.
15. Patel, A.V.; Rodriguez, C.; Bernstein, L.; Chao, A.; Thun, M.J.; Calle, E.E. Obesity, recreational physical activity, and risk of pancreatic cancer in a large U.S. Cohort. Cancer. Epidemiol. Biomarkers Prev. 2005, 14, 459-466.
16. Berrington de Gonzalez, A.; Sweetland, S.; Spencer E. A meta-analysis of obesity and the risk of pancreatic cancer. Br. J. Cancer. 2003, 89, 519-523.
17. Vrieling, A.; Verhage, B.A.; van Duijnhoven, F.J.; Jenab, M.; Overvad, K.; Tjønneland, A.; Olsen, A.; Clavel-Chapelon, F.; Boutron-Ruault, M.C.; Kaaks, R.; et al. Fruit and vegetable consumption and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition. Int. J. Cancer 2009, 124, 1926-1934.
18. Batty, G.D.; Kivimaki, M.; Morrison, D.; Huxley, R.; Smith, G.D.; Clarke, R.; Marmot, M.G.; Shipley, MJ. Risk factors for pancreatic cancer mortality: Extended follow-up of the original Whitehall Study. Cancer Epidemiol. Biomark. Prev. 2009, 18, 673-675.
19. Landi, S. Genetic predisposition and environmental risk factors to pancreatic cancer: A review of the literature. Mutat. Res. 2009, 681, 299-307.
20. Lowenfels, A.B.; Maisonneuve, P. Epidemiology and risk factors for pancreatic cancer. Best Pract. Res. Clin. Gastroenterol. 2006, 20, 197-209.
21. Curado, M.P.; Edwards, B.K.; Shin, H.R.; Storm, H. Cancer Incidence in Five Continents; IARC Scientific Publicaitons: Lyon, Frrance, 2007; Volume 9, No. 160.
22. Garland, C.F.; Garland, F.C. Do sunlight and vitamin D reduce the likelihood of colon cancer? Int. J. Epidemiol. 1980, 9, 227-231.
23. Schwartz, G.G.; Hulka, B.S. Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res. 1990, 10, 1307-1311.
24. Gorham, E.D.; Garland, F.C.; Garland, C.F. Sunlight and breast cancer incidence in the USSR. Int. J. Epidemiol. 1990, 19, 820-824.
25. Vogelstein, B.; Kinzler, K.W. Cancer genes and the pathways they control. Nat. Med. 2004, 10, 789-799.
26. Hruban, R.H.; Maitra, A.; Goggins, M. Update on pancreatic intraepithelial neoplasia. Int. J. Clin. Exp. Pathol. 2008, 1, 306-316.
27. Takaori, K. Current understanding of precursors to pancreatic cancer. J. Hepatobiliary. Pancreat. Surg. 2007, 14, 217-223.
28. Hruban, R.H.; Adsay, N.V.; Albores-Saavedra, J.; Compton, C.; Garrett, E.S.; Goodman, S.N.; Kern, S.E.; Klimstra, D.S.; Klöppel, G.; Longnecker, D.S.; Lüttges, J.; Offerhaus, G.J. Pancreatic intraepithelial neoplasia: A new nomenclature and classification system for pancreatic duct lesions. Am. J. Surg. Pathol. 2001, 25, 579-586.
29. Hruban, R.H.; Takaori, K.; Klimstra, D.S.; Adsay, N.V.; Albores-Saavedra, J.; Biankin, A.V.; Biankin, S.A.; Compton, C.; Fukushima, N.; Furukawa, T.; et al. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am. J. Surg. Pathol. 2004, 28, 977-987.
30. Almoguera, C.; Shibata, D.; Forrester, K.; Martin, J.; Arnheim, N.; Perucho, M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988, 53, 549-554.
31. Caldas, C.; Hahn, S.A.; da Costa, L.T.; Redston, M.S.; Schutte, M.; Seymour, A.B.; Weinstein, C.L.; Hruban, R.H.; Yeo, C.J.; Kern, S.E. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat. Genet. 1994, 8, 27-32, Erratum in: Nat. Genet. 1994, 8, 410.
32. Redston, M.S.; Caldas, C.; Seymour, A.B.; Hruban, R.H.; da Costa, L.; Yeo, C.J.; Kern, S.E. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res. 1994, 54, 3025-3033.
33. Hahn, S.A.; Schutte, M.; Hoque, A.T.; Moskaluk, C.A.; da Costa, L.T.; Rozenblum, E.; Weinstein, C.L.; Fischer, A.; Yeo, C.J.; Hruban, R.H.; Kern, S.E. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996, 271, 350-353.
34. Li, C.; Heidt, D.G.; Dalerba, P.; Burant, C.F.; Zhang, L.; Adsay, V.; Wicha, M.; Clarke, M.F.; Simeone, DM. Identification of pancreatic cancer stem cells. Cancer Res. 2007, 67, 1030-1037.
35. Hermann, P.C.; Huber, S.L.; Herrler, T.; Aicher, A.; Ellwart, J.W.; Guba, M.; Bruns, C.J.; Heeschen, C. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007, 1, 313-323.
36. Neoptolemos, J.P.; Stocken, D.D.; Friess, H.; Bassi, C.; Dunn, J.A.; Hickey, H.; Beger, H.; Fernandez-Cruz, L.; Dervenis, C.; Lacaine, F.; Falconi, M.; Pederzoli, P.; Pap, A.; Spooner, D.; Kerr, D.J.; Büchler, M.W. European Study Group for Pancreatic Cancer. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N. Engl. J. Med. 2004, 350, 1200-1210. Erratum in: N. Engl. J. Med. 2004, 351, 726.
37. Oettle, H.; Post, S.; Neuhaus, P.; Gellert, K.; Langrehr, J.; Ridwelski, K.; Schramm, H.; Fahlke, J.; Zuelke, C.; Burkart, C.; Gutberlet, K.; Kettner, E.; Schmalenberg, H.; Weigang-Koehler, K.; Bechstein, WO.; Niedergethmann, M.; Schmidt-Wolf, I.; Roll, L.; Doerken, B.; Riess, H. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. JAMA 2007, 297, 267-277.
38. Regine, W.F.; Winter, K.A.; Abrams, R.A.; Safran, H.; Hoffman, J.P.; Konski, A.; Benson, A.B.; Macdonald, J.S.; Kudrimoti, M.R.; Fromm, M.L.; Haddock, M.G.; Schaefer, P.; Willett, C.G.; Rich, T.A. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: A randomized controlled trial. JAMA 2008, 299, 1019-1026.
39. Herman, J.M.; Swartz, M.J.; Hsu, C.C.; Winter, J.; Pawlik, T.M.; Sugar, E.; Robinson, R.; Laheru, D.A.; Jaffee, E.; Hruban, R.H.; Campbell, K.A.; Wolfgang, C.L.; Asrari, F.; Donehower, R.; Hidalgo, M.; Diaz, L.A., Jr.; Yeo, C.; Cameron, JL.; Schulick, RD.; Abrams, R. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: Results of a large, prospectively collected database at the Johns Hopkins Hospital. J. Clin. Oncol. 2008, 26, 3503-3510.
40. Renouf, D.; Moore, M. Evolution of systemic therapy for advanced pancreatic cancer. Expert. Rev. Anticancer Ther. 2010, 10, 529-540.
41. Mozolowski, W.; Sniadecki, J. On the cure of rickets. Nature 1939, 143, 121.
42. Palm, T. The geographical distribution and etiology of rickets. Practitiner 1890, 45, 270-279, 321-342.
43. McCollum, E.V.; Simmons, N.; Pitz, W. The relaitn of the unidentified dietary factors, the fat-soluble A and water soluble B of the diet to the growth promoting properties of milk. J. Biol. Chem. 1916, 27, 33-38.
44. McCollum, E.V.; Simmonds N.; Becker, J.E.; Shipley, P.G. An experimental demonstratin of the existence of a vitamin which promotes calcium deposition. J. Biol. Chem. 1922, 53, 293-298.
45. Huldshinsky, K. Heilung von rachitis durch kunstlich hohensonne. Deut. Med. Wochenschr. 1919, 45, 712-713.
46. Steenbock, H. Black fat-soluble vitamins. XVII. The induction of growth-promoting and calcifying properties in a ration by exposure to ultraviolet light. J. Biol. Chem. 1924, 61, 405-422.
47. Holick, M.F. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am. J. Clin. Nutr. 2004, 80, 1678S-1688S.
48. Holick, M.F.; MacLaughlin, J.A.; Clark, M.B.; Holick, S.A.; Potts, J.T., Jr.; Anderson, R.R.; Blank, I.H.; Parrish, J.A.; Elias, P. Photosynthesis of previtamin D3 in human skin and the physiologic consequences. Science 1980, 210, 203-205.
49. MacLaughlin, J.A.; Anderson, R.R.; Holick, M.F. Spectral character of sunlight modulates photosynthesis of previtamin D3 and its photoisomers in human skin. Science 1982, 216, 1001-1003.
50. Segart, S. Vitamin D regulation of cathelicidin in the skin. Toward a renaissance of vitamin D in dermatology? J. Invest. Dermatol. 2008, 128, 773-775.
51. Lehmann, B.; Meurer, M. Vitamin D metabolism. Dermatol. Ther. 2010, 23, 2-12.
52. Schuster, I. Cytochromes P450 are essential players in the vitamin D signaling system. Biochim Biophys. Acta 2011, 1814, 186-199.
53. Zehnder, D.; Bland, R.; Williams, M.C.; McNinch, R.W.; Howie, A.J.; Stewart, P.M.; Hewison, M. Extrarenal expression of 25-hydroxyvitamin D3-1 alpha-hydroxylase. J. Clin. Endocrinol. Metab. 2001, 86, 888-894.
54. Omdahl, J.L.; Morris, H.A.; May, B.K. Hydroxylase enzymes of the vitamin D pathway: Expression, function, and regulation. Annu. Rev. Nutr. 2002, 22, 139-166.
55. Chiang, K.C.; Chen, T.C. Vitamin D for the prevention and treatment of pancreatic cancer. World J. Gastroenterol. 2009, 15, 3349-3354.
56. Schwartz, G.G.; Eads, D.; Rao, A.; Cramer, S.D.; Willingham, M.C.; Chen, T.C.; Jamieson, D.P.; Wang, L.; Burnstein, K.L.; Holick, M.F.; Koumenis, C. Pancreatic cancer cells express 25-Hydroxyvitamin D-1 {alpha}-hydroxylase and their proliferation is inhibited by the prohormone 25-hydroxyvitamin D3. Carcinogenesis 2004, 25, 1015-1026.
57. Haussler, M.R.; Haussler, C.A.; Jurutka, P.W.; Thompson, P.D.; Hsieh, J.C.; Remus, L.S.; Selznick, S.H.; Whitfield, G.K. The vitamin D hormone and its nuclear receptor: Molecular actions and disease states. J. Endocrinol. 1997, 154, S57-73.
58. Ramagopalan, S.V.; Heger, A.; Berlanga, A.J.; Maugeri, N.J.; Lincoln, M.R.; Burrell, A.; Handunnetthi, L.; Handel, A.E.; Disanto, G.; Orton, S.M.; Watson, C.T.; Morahan, J.M.; Giovannoni, G.; Ponting, C.P.; Ebers, G.C.; Knight, J.C. A ChIP-seq defined genome-wide map of vitamin D receptor binding: Associations with disease and evolution. Genome Res. 2010, 20, 1352-1360.
59. Stumpf, W.E.; Sar, M.; Reid, F.A.; Tanaka, Y.; DeLuca, H.F. Target cells for 1,25-dihydroxyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary, and parathyroid. Science 1979, 206, 1188-1190.
60. Feldman, D.; Malloy, P.J.; Krishnan, A.V.; Balint, E. Vitamin D: Biology, action, and clinical implications. In Osteoporosis, 3rd edition; Marcus, R., Feldman, D., Nelson, D.A., Rosen, C.J., Eds.; Academic Press: San Diego, CA, USA, 2008; Volume 1, pp. 317-382.
61. Adams, J.S.; Hewison, M. Update in vitamin D. J. Clin. Endocrinol. Metab. 2010, 471-478.
62. Bikle, D. Nonclassic actions of vitamin D. J. Clin. Endocrinol. Metab. 2009, 94, 26-34.
63. Colston, K.; Hirt, M.; Feldman, D. Organ distribution of the cytoplasmic 1,25-dihydroxycholecalciferol receptor in various mouse tissues. Endocrinology. 1980, 107, 1916-1922.
64. Chen, T.C.; Holick, M.F. Vitamin D and prostate cancer prevention and treatment. Trends Endocrinol. Metab. 2003, 14, 423-430.
65. Skowronski, R.J.; Peehl, D.M.; Feldman, D. Vitamin D and prostate cancer: 1,25-Dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 1993, 132, 1952-1960.
66. Chiang, K.C.; Persons, K.S.; Istfan, N.W.; Holick, M.F.; Chen, T.C. Fish oil enhances the antiproliferative effect of 1 alpha, 25-dihydroxyvitamin D3 on liver cancer cells. Anticancer Res. 2009, 29, 3591-3596, Erratum in: Anticancer Res. 2010, 30, 277, Anticancer Res. 2010, 30, 1033.
67. Flanagan, J.N.; Zheng, S.; Chiang, K.C.; Kittaka, A.; Sakaki, T.; Nakabayashi, S.; Zhao, X.; Spanjaard, R.A.; Persons, K.S.; Mathieu, J.S.; Holick, M.F.; Chen, T.C. Evaluation of 19-nor-2alpha-(3-hydroxypropyl)-1 alpha, 25-dihydroxyvitamin D3 as a therapeutic agent for androgen-dependent prostate cancer. Anticancer Res. 2009, 29, 3547-3553.
68. Kawa, S.; Nikaido, T.; Aoki, Y.; Zhai, Y.; Kumagai, T.; Furihata, K.; Fujii, S.; Kiyosawa, K. Vitamin D analogues up-regulate p21 and p27 during growth inhibition of pancreatic cancer cell lines. Br. J. Cancer 1997, 76, 884-889.
69. Schwartz, G.G.; Eads, D.; Naczki, C.; Northrup, S.; Chen, T.C.; Koumenis, C. 19-nor-1 alpha, 25-dihydroxyvitamin D2 (paricalcitol) inhibits the proliferation of human pancreatic cancer cells in vitro and in vivo. Cancer Biol. Ther. 2008, 7, 430-436.
70. Kawa, S.; Yoshizawa, K.; Tokoo, M.; Imai, H.; Oguchi, H.; Kiyosawa, K.; Homma, T.; Nikaido.; Furihata, K. Inhibitory effect of 220-oxa-1,25-dihydroxyvitamin D3 on the proliferation of pancreatic cancer cell lines. Gastroenterology 1996, 110, 1605-1613.
71. Colston, K.W.; James, S.Y.; Ofori-Kuragu, E.A.; Binderup, L.; Grant, A.G. Vitamin D receptors and anti-proliferative effects of vitamin D derivatives in human pancreatic carcinoma cells in vivo and in vitro. Br. J. Cancer 1997, 76, 1017-1020.
72. Pettersson, F.; Colston, K.W.; Dalgleish, A.G. Differential and antagonistic effects of 9-cis-retinoic acid and vitamin D analogues on pancreatic cancer cells in vitro. Br. J. Cancer 2000, 83, 239-245.
73. Zugmaier, G.; Jäger, R.; Grage, B.; Gottardis, M.M.; Havemann, K.; Knabbe, C. Growth-inhibitory effects of vitamin D analogues and retinoids on human pancreatic cancer cells. Br. J. Cancer 1996, 73, 1341-1346.
74. Evans, T.R.; Colston, K.W.; Lofts, F.J.; Cunningham, D.; Anthoney, D.A.; Gogas, H.; de Bono, J.S.; Hamberg, K.J.; Skov, T.; Mansi, J.L. A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer. Br. J. Cancer 2002, 86, 680-685.
75. Blanke, C.D.; Beer, T.M.; Todd, K.; Mori, M.; Stone, M.; Lopez, C. Phase II study of calcitriol-enhanced docetaxel in patients with previouslyuntreated metastatic or locally advanced pancreatic cancer. Invest. New Drugs 2009, 27, 374-378.
76. Persons, K.S.; Eddy, V.J.; Chadid, S.; Deoliveira, R.; Saha, A.K.; Ray, R. Anti-growth effect of 1,25-dihydroxyvitamin D3-3-bromoacetate alone or in combination with 5-amino-imidazole-4-carboxamide-1-beta-4-ribofuranoside in pancreatic cancer cells. Anticancer Res. 2010, 30, 1875-1880.
77. Chen, T.C.; Persons, K.S.; Zheng, S.; Mathieu, J.; Holick, M.F.; Lee, Y.F.; Bao, B.; Arai, M.A.; Kittaka, A. Evaluation of C-2-substituted 19-nor-1D, 25-dihydroxyvitamin D3 analogs as therapeutic agents for prostate cancer. J. Steroid Biochem. Mol. Biol. 2007, 103, 717-720.
78. Iglesias-Gato, D.; Zheng, S.; Flanagan, J.N.; Jiang, L.; Sakaki, T.; Nakabayashi, S.; Kittaka, A.; LeBrasseur, N.K.; Norstedt, G.; Chen, T.C. The C-2 substituted 19-nor-1D, 25-dihydroxyvitamin D3 analog, MART-10, has enhanced chemotherapeutic potency in PC-3 prostate cancer cells. 2010, in preparation.
79. Skinner, H.G.; Michaud, D.S.; Giovannucci, E.; Willett, W.C.; Colditz, G.A.; Fuchs, C.S. Vitamin D intake and the risk for pancreatic cancer in two cohort studies. Cancer Epidemiol. Biomarkers Prev. 2006, 15, 1688-1695.
80. Stolzenberg-Solomon, R.Z.; Vieth, R.; Azad, A.; Pietinen, P.; Taylor, P.R.; Virtamo, J.; Albanes, D. A prospective nested case-control study of vitamin D status and pancreatic cancer risk in male smokers. Cancer Res. 2006, 66, 10213-10219.
81. Grant, W.B. An ecologic study of cancer mortality rates in Spain with respect to indices of solar UVB irradiance and smoking. Int. J. Cancer 2007, 120, 1123-1128.
82. Boscoe, F.P.; Schymura, M.J. Solar ultraviolet-B exposure and cancer incidence and mortality in the United States, 1993-2002. BMC Cancer 2006, 6, 264.
83. Tuohimaa, P.; Pukkala, E.; Scélo, G.; Olsen, J.H.; Brewster, D.H.; Hemminki, K.; Tracey, E.; Weiderpass, E.; Kliewer, E.V.; Pompe-Kirn, V.; McBride, M.L.; Martos, C.; Chia, K.S.; Tonita, J.M.; Jonasson, J.G.; Boffetta, P.; Brennan, P. Does solar exposure, as indicated by the non-melanoma skin cancers, protect from solid cancers: Vitamin D as a possible explanation. Eur. J. Cancer 2007, 43, 1701-1712.
84. Mizoue, T. Ecological study of solar radiation and cancer mortality in Japan. Health Phys. 2004, 87, 532-538.
85. Stolzenberg-Solomon, R.Z.; Hayes, R.B.; Horst, R.L.; Anderson, K.E.; Hollis, B.W.; Silverman, D.T. Serum vitamin D and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian screening trial. Cancer Res. 2009, 69, 1439-1447.
86. Yin, L.; Grandi, N.; Raum, E.; Huang, U.; Arndt, V.; Brenner, H. Meta-analysis: Serum vitamin D and breast cancer risk. Eur. J. Cancer 2010, 46, 2196-2205.
87. Stolzenberg-Solomon, R.Z.; Jacobs, E.J.; Arslan, A.A.; Qi, D.; Patel, A.V.; Helzlsouer, K.J.; Weinstein, S.J.; McCullough, M.L.; Purdue, M.P.; Shu, X.O.; Snyder, K.; et al. Circulating 25-hydroxyvitamin D and risk of pancreatic cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am. J. Epidemiol. 2010, 172, 81-93.
88. Mohr, S.B.; Garland, C.F.; Gorham, E.D.; Grant, W.B.; Garland, F.C. Ultraviolet B irradiance and vitamin D status are inversely associated with incidence rates of pancreatic cancer worldwide. Pancreas 2010, 39, 669-674.
89. Giovannucci, E.; Liu, Y.; Rimm, E.B.; Hollis, B.W.; Fuchs, C.S.; Stampfer, M.J.; Willett, W.H. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. JNCI 2006, 98, 451-459.
90. Kato, I.; Tajima, K.; Kuroishi, T.; Tominaga, S. Latitude and pancreatic cancer. Jpn. J. Clin. Oncol. 1985, 15, 403-413.
91. Neale, R.E.; Youlden, D.R.; Krnjacki, L.; Kimlin, M.G.; van der Pols, J.C. Latitude variation in pancreatic cancer mortality in Australia. Pancreas 2009, 38, 387-390.
92. Stolzenberg-Solomon, R.Z.; Graubard, B.I.; Chari, S.; Limburg, P.; Taylor, P.R.; Virtamo, J.; Albanes, D. Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA 2005, 294, 2872-2878.
93. Huxley, R.; Ansary-Moghaddam, A.; Berrington de González, A.; Barzi, F.; Woodward, M. Type-II diabetes and pancreatic cancer: A meta-analysis of 36 studies. Br. J. Cancer 2005, 92, 2076-2083.
94. Michaud, D.S.; Wolpin, B.; Giovannucci, E.; Liu, S.; Cochrane, B.; Manson, J.E.; Pollak, M.N.; Ma, J.; Fuchs, C.S. Prediagnostic plasma C-peptide and pancreatic cancer risk in men and women. Cancer Epidemiol. Biomarkers Prev. 2007, 16, 2101-2109.
95. Hennig, R.; Ding, X.Z.; Adrian, T.E. On the role of the islets of Langerhans in pancreatic cancer. Histol. Histopathol. 2004, 19, 999-1011.
96. Mathieu, C.; Gysemans, C.; Giulietti, A.; Bouillon, R. Vitamin D and diabetes. Diabetologia 2005, 48, 1247-1257.
97. Maestro, B.; Campión, J.; Dávila, N.; Calle, C. Stimulation by 1,25-dihydroxyvitamin D3 of insulin receptor expression and insulin responsiveness for glucose transport in U-937 human promonocytic cells. Endocr. J. 2000, 47, 383-391.
98. Maestro, B.; Dávila, N.; Carranza, M.C.; Calle, C. Identification of a Vitamin D response element in the human insulin receptor gene promoter. J. Steroid Biochem. Mol. Biol. 2003, 84, 223-230.